HC Wainwright Has Bearish Forecast for SLDB FY2025 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Research analysts at HC Wainwright decreased their FY2025 earnings estimates for Solid Biosciences in a note issued to investors on Wednesday, November 5th. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($1.98) per share for the year, down from their prior estimate of ($1.87). The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q4 2025 earnings at ($0.51) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.52) EPS, Q3 2026 earnings at ($0.53) EPS, FY2026 earnings at ($2.12) EPS and FY2027 earnings at ($1.76) EPS.

Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06).

Several other analysts have also commented on SLDB. Chardan Capital reiterated a “buy” rating and set a $15.00 price objective on shares of Solid Biosciences in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Solid Biosciences in a research report on Wednesday, October 8th. Barclays set a $9.00 price target on Solid Biosciences and gave the stock an “overweight” rating in a report on Tuesday. JPMorgan Chase & Co. dropped their price target on Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Wall Street Zen lowered shares of Solid Biosciences from a “hold” rating to a “sell” rating in a research report on Sunday, October 19th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Solid Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $14.70.

Solid Biosciences Stock Up 7.4%

NASDAQ SLDB opened at $4.22 on Friday. The company has a 50 day moving average price of $5.59 and a 200 day moving average price of $5.04. Solid Biosciences has a 52 week low of $2.41 and a 52 week high of $7.37. The firm has a market cap of $328.78 million, a PE ratio of -1.69 and a beta of 2.75.

Institutional Investors Weigh In On Solid Biosciences

A number of large investors have recently bought and sold shares of the company. Legal & General Group Plc increased its holdings in Solid Biosciences by 208.6% in the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock worth $29,000 after buying an additional 4,063 shares during the period. Ameritas Investment Partners Inc. lifted its stake in Solid Biosciences by 205.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after acquiring an additional 4,534 shares during the period. American Century Companies Inc. boosted its holdings in shares of Solid Biosciences by 10.6% in the 1st quarter. American Century Companies Inc. now owns 51,835 shares of the company’s stock valued at $192,000 after acquiring an additional 4,978 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Solid Biosciences by 8.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 68,607 shares of the company’s stock valued at $254,000 after acquiring an additional 5,220 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Solid Biosciences by 80.7% in the first quarter. China Universal Asset Management Co. Ltd. now owns 15,308 shares of the company’s stock worth $57,000 after acquiring an additional 6,836 shares during the period. Hedge funds and other institutional investors own 81.46% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.